Research ExplorerScientific StaffGlenn Geidel Publications

Dr.med. ID: 9506335

Glenn Geidel

graph of relations
Affiliations
1 - 10 out of 10Page size: 50

Publications

  1. 2024

  2. Sentinel lymph node risk prognostication in primary cutaneous melanoma through tissue-based profiling, potentially redefining the need for sentinel lymph node biopsy

    Kött, J., Zimmermann, N., Zell, T., Rünger, A., Heidrich, I., Geidel, G., Smit, D. J., Hansen, I., Abeck, F., Schadendorf, D., Eggermont, A., Puig, S., Hauschild, A. & Gebhardt, C., 05.2024, In: EUR J CANCER. 202, 113989.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  3. High Serum Levels of CCL20 Are Associated with Recurrence and Unfavorable Overall Survival in Advanced Melanoma Patients Receiving Immunotherapy

    Kött, J., Hoehne, I., Heidrich, I., Zimmermann, N., Reese, K-L., Zell, T., Geidel, G., Rünger, A. M., Schneider, S., Pantel, K., Smit, D. J. & Gebhardt, C., 29.04.2024, In: CANCERS. 16, 9, 1737.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  4. 2023

  5. Neoadjuvant cemiplimab induces durable complete response in locally advanced cutaneous squamous cell carcinoma

    Geidel, G., Adam, L., Rünger, A., Menz, A., Kött, J., Haalck, T. & Gebhardt, C., 12.2023, In: J EUR ACAD DERMATOL. 37, 12, p. e1414-e1416

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  6. Prognostic value of von Willebrand factor levels in patients with metastatic melanoma treated by immune checkpoint inhibitors

    Stadler, J-C., Keller, L., Mess, C., Bauer, A. T., Koett, J., Geidel, G., Heidrich, I., Vidal-Y-Sy, S., Andreas, A., Stramaglia, C., Sementsov, M., Haberstroh, W., Deitert, B., Hoehne, I. L., Reschke, R., Haalck, T., Pantel, K., Gebhardt, C. & Schneider, S. W., 05.2023, In: J IMMUNOTHER CANCER. 11, 5, e006456.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  7. 2022

  8. Activated Eosinophils Predict Longer Progression-Free Survival under Immune Checkpoint Inhibition in Melanoma

    Ammann, N. L., Schwietzer, Y. F., Mess, C., Stadler, J-C., Geidel, G., Kött, J., Pantel, K., Schneider, S. W., Utikal, J., Bauer, A. T. & Gebhardt, C., 18.11.2022, In: CANCERS. 14, 22, 5676.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  9. Emerging precision diagnostics in advanced cutaneous squamous cell carcinoma

    Geidel, G., Heidrich, I., Kött, J., Schneider, S. W., Pantel, K. & Gebhardt, C., 23.03.2022, In: NPJ PRECIS ONCOL. 6, 1, 17.

    Research output: SCORING: Contribution to journal › SCORING: Review article › Research

  10. Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report

    Geidel, G., Rünger, A., Schneider, S. W. & Gebhardt, C., 01.2022, In: J EUR ACAD DERMATOL. 36, S1, p. 49-52 4 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

  11. 2021

  12. Adjuvante Pembrolizumab-assoziierte Hyperprogression eines Melanoms im Stadium III

    Ammann, N. L., Geidel, G., Schneider, S. W. & Gebhardt, C., 09.2021, In: J DTSCH DERMATOL GES. 19, 9, p. 1341-1345 5 p.

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  13. Adjuvant pembrolizumab-related hyperprogression in stage III melanoma

    Ammann, N. L., Geidel, G., Schneider, S. W. & Gebhardt, C., 09.2021, In: J DTSCH DERMATOL GES. 19, 9, p. 1341-1345 5 p.

    Research output: SCORING: Contribution to journal › Letter › Research › peer-review

  14. Hyperprogression fortgeschrittener Melanomerkrankung unter Pembrolizumab adjuvant

    Geidel, G., Ammann, N. L., Schneider, S. W. & Gebhardt, C., 07.2021, In: J DTSCH DERMATOL GES. 19, S1, p. 37-39 3 p.

    Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review